Barrons·10h ago
Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its AllureThe tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
Medtronic's revenue growth has accelerated to 13.7% year-over-year in Q1 FY2027, suggesting its portfolio optimization strategy is gaining traction. However, this growth is accompanied by significant margin volatility and erratic cash conversion, with operatin...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 13.7% year-over-year in Q1 FY2027, but operating margin remains constrained at 18.1% due to elevated SG&A spending of $3.2B (33% of revenue), suggesting growth investments are currently offsetting scale benefits.
Medtronic is a global leader in medical technology, services, and solutions, collaborating to address healthcare challenges.
Medtronic's strong competitive positioning and wide moat support its long-term business resilience and growth.
The company's innovation pipeline, including products like the Stealth AXiS surgical system, drives future growth opportunities.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 1, 2026 | $1.45+4.3% vs $1.39 | $9.8B+2.2% vs $9.5B |
Q3 2026 Jun 3, 2026 | $1.55+0.6% vs $1.54 | $9.8B+1.9% vs $9.6B |
Q1 2026 Feb 17, 2026 | $1.36+1.5% vs $1.34 | $9.0B+1.2% vs $8.9B |
Q4 2025 Nov 18, 2025 | $1.36+3.8% vs $1.31 | $9.0B+1.1% vs $8.9B |
The tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
Kevin Warsh has stated that inflation is the Fed's primary target right now. Medtronic has a well-above-market 3.2% yield, and its medical devices aren't optional for most people.
Coding approvals reflect growing clinical evidence and physician adoption of Medtronic solutions addressing urge urinary incontinence and hypertension GALWAY, Ireland, Oct. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for the treatment of urge urinary incontinence and Symplicity Spyral™ renal denervation (RDN) system for the treatment of uncontrolled hypertension. The new codes, which will replace existing Category III codes, are effective January 2028.
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Benchmark MDT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Medtronic plc (MDT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $86.38 | $110.9B | 23.16 | 8.43% | 13.2% | 9.76% | 3.27% | |
| $97.50 | $169.83B | 26.21 | 5.67% | 13.91% | 12.09% | — | |
| $42.60 | $63.32B | 21.96 | 19.87% | 17.47% | 14.76% | — | |
| $85.15 | $49.03B | 46.53 | 11.55% | 15.43% | 9.66% | — | |
| $275.43 | $105.59B | 32.79 | 11.16% | 14.43% | 16.36% | — | |
| $88.29 | $17.08B | 24.87 | 7.2% | 9.48% | 6.36% | — |
Medtronic plc (MDT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Medtronic plc (MDT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 1, 2026·SEC
Jun 3, 2026·SEC
May 18, 2026·SEC
Get notified when MDT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Medtronic plc (MDT) stock FAQ — growth, dividends, profitability & financials explained
Medtronic plc (MDT) reported $37.54B in revenue for fiscal year 2026. This represents a 1440% increase from $2.44B in 1997.
Medtronic plc (MDT) grew revenue by 8.4% over the past year. This is steady growth.
Yes, Medtronic plc (MDT) is profitable, generating $5.23B in net income for fiscal year 2026 (13.2% net margin).
Yes, Medtronic plc (MDT) pays a dividend with a yield of 3.27%. This makes it attractive for income-focused investors.
Medtronic plc (MDT) has a return on equity (ROE) of 9.8%. This is below average, suggesting room for improvement.
Medtronic plc (MDT) generated $6.13B in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
